Amphetamines (Mixed Amphetamine Salts, Lisdexamfetamine)
Treatment for Adhd
Typical Dosage: 5-40mg daily (amphetamine equivalent), tailored to individual
Effectiveness
90%
Safety Score
60%
Clinical Trials
7
Participants
400K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
5-40mg daily (amphetamine equivalent), tailored to individual
Time to Effect
Immediate (within 30-60 minutes for IR, 1-2 hours for ER)
Treatment Duration
Lifetime (as needed)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$300
Side Effect Mgmt:$75
Total Annual:$1,375
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$18,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$1,718.75
Cost per Remission
$3,055.56
Amphetamines (Mixed Amphetamine Salts, Lisdexamfetamine) Outcomes
for Adhd
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+80%
Remission Rate
+45%
Common Side Effects
Insomnia
+30%
Decreased appetite/weight loss
+30%
Headache
+15%
Abdominal pain
+12%
Irritability/anxiety
+12%
Increased heart rate/blood pressure
+8%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
7 completed trials for Amphetamines (Mixed Amphetamine Salts, Lisdexamfetamine) in Adhd
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD
NCT00557011COMPLETEDPHASE2
52 participants
INTERVENTIONAL
Started: Sep 1, 2004
Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
NCT01010750COMPLETEDPHASE1
18 participants
INTERVENTIONAL
Houston, United States
Started: Jan 5, 2010
The Reinforcing Mechanisms of Smoking in Adult ADHD
NCT00573859COMPLETEDPHASE1, PHASE2
27 participants
INTERVENTIONAL
Irvine, United States
Started: Sep 1, 2006
Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)
NCT00889915COMPLETEDPHASE4
228 participants
INTERVENTIONAL
Durham, United States
Started: Apr 1, 2009
Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse)
NCT01070394COMPLETEDPHASE4
40 participants
INTERVENTIONAL
New York, United States
Started: Feb 1, 2010
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits
NCT01399827COMPLETEDPHASE2
2 participants
INTERVENTIONAL
Boston, United States
Started: Feb 1, 2012
Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder
NCT01074294COMPLETEDPHASE2
740 participants
INTERVENTIONAL
Little Rock, United States +34 more
Started: Mar 16, 2010